Cell Therapy Brochure | Cell Therapy
December 15, 2023
Cell Therapy Brochure | Cell Therapy
December 15, 2023
December 15, 2023
December 15, 2023
October 16, 2023
October 16, 2023
Targeted protein degraders (TPDs) offer great promise in treating some of the most challenging diseases. But clinical development is fraught with complex biomarker challenges.
To succeed, you must deeply understand your TPD’s mechanisms of action, accurately monitor target degradation to optimize dosing, and unveil the causes of resistance — which is no easy feat.
Download our brochure today and find out how, with deep TPD expertise and a comprehensive multi-omics approach, we can steer you through the complexities of understanding TPD potency, dose optimization, and resistance mechanisms, helping you increase your chances of TPD clinical development success.
As a global research organization, we prioritize your study goals and clinical trial needs above all else. We aim to provide you with easy, accessible, and comprehensive technologies spanning a multitude of therapeutic areas. Discover our range of services in immunology, histopathology, proteomics, genomics, as well as related ML/AI and sample logistics services.
Targeted protein degraders (TPDs) offer great promise in treating some of the most challenging diseases. But clinical development is fraught with complex biomarker challenges.
To succeed, you must deeply understand your TPD’s mechanisms of action, accurately monitor target degradation to optimize dosing, and unveil the causes of resistance — which is no easy feat.
Download our brochure today and find out how, with deep TPD expertise and a comprehensive multi-omics approach, we can steer you through the complexities of understanding TPD potency, dose optimization, and resistance mechanisms, helping you increase your chances of TPD clinical development success.
As a global research organization, we prioritize your study goals and clinical trial needs above all else. We aim to provide you with easy, accessible, and comprehensive technologies spanning a multitude of therapeutic areas. Discover our range of services in immunology, histopathology, proteomics, genomics, as well as related ML/AI and sample logistics services.
August 4, 2023
CellCarta’s immuno-MRM assays, based on immunoaffinity enrichment of peptides coupled to liquid chromatography-targeted multiple reaction monitoring (LC-MRM), allow for sensitive and precise protein quantification. We offer nine CPTAC validated panels to investigate DNA damage response (DDR1, 2, 3), immuno-oncology (IO-1, 2, 3), Ras-MAPK signaling pathway (Ras-MAPK1, 2), and human epidermal growth factor receptor 2 (HER2) expression. Our team continually develops new panels, combining up to 50 targets (listed below), for your specific needs. With CAP-accredited and CLIA-certified sites, we provide the highest standard of quality.
Contact us for any custom development.
August 4, 2023
CellCarta’s immuno-MRM assays, based on immunoaffinity enrichment of peptides coupled to liquid chromatography-targeted multiple reaction monitoring (LC-MRM), allow for sensitive and precise protein quantification. We offer nine CPTAC validated panels to investigate DNA damage response (DDR1, 2, 3), immuno-oncology (IO-1, 2, 3), Ras-MAPK signaling pathway (Ras-MAPK1, 2), and human epidermal growth factor receptor 2 (HER2) expression. Our team continually develops new panels, combining up to 50 targets (listed below), for your specific needs. With CAP-accredited and CLIA-certified sites, we provide the highest standard of quality.
Contact us for any custom development.
July 26, 2023
July 26, 2023
